Chronic Myeloid Leukemia
Pipeline by Development Stage
Drug Modality Breakdown
Chronic Myeloid Leukemia is a $3.0B market characterized by mature, stable performance dominated by established tyrosine kinase inhibitors with approaching patent cliffs.
Key Trends
- Consolidation around BCR-ABL inhibitors with established resistance profiles and clinical outcomes
- Patent cliff risk in 2026-2027 (SPRYCEL, SYNRIBO) threatening $511M in annual revenue
- Shift toward newer-generation TKIs (asciminib, bosutinib) and combination strategies for resistant disease
Career Verdict
CML is a stable but mature oncology niche—best for professionals seeking established workflows rather than high-growth opportunity; strong for commercial roles but limited pipeline upside.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | SPRYCEL (dasatinib) | Bristol Myers Squibb | $510M | 17% | LOE_APPROACHING | Declining | Post-LOE |
| 2 | TASIGNA (nilotinib) | Novartis | $395M | 13% | PEAK | Stable | 5.9yr |
| 3 | BOSULIF (bosutinib) | Pfizer | $199M | 7% | PEAK | Stable | 7.8yr |
| 4 | SCEMBLIX (asciminib) | Novartis | $114M | 4% | PEAK | Growing | 13.5yr |
| 5 | GLEEVEC (imatinib mesylate) | Novartis | $73M | 2% | LOE_APPROACHING | Declining |
Drug Class Breakdown
patent cliff approaching 2026
stable market leader
growing adoption
declining as original standard
emerging resistance solution
Career Outlook
StableCML is a stable, well-defined indication with predictable patient populations, established treatment algorithms, and limited clinical surprises—ideal for professionals seeking secure roles in a mature market. The 2026-2027 patent cliff will create commercial strategy disruption and potential layoffs at BMS, but Novartis and Pfizer remain well-positioned through 2030+. Pipeline innovation is incremental rather than exponential, limiting upside for researchers or early-stage drug development specialists.
Breaking In
Enter via commercial or manufacturing teams at Novartis/Pfizer to avoid exposure to BMS's 2026 cliff; focus on master BCR-ABL resistance biology and payer narratives for long-term relevance.
For Experienced Professionals
Leverage CML stability to lead portfolio diversification into adjacent indications (ALL, Ph+ leukemias) or mentor next-generation kinase inhibitor development; avoid pure CML mono-focus past 2027.
In-Demand Skills
Best For
Hiring Landscape
Total of 3,627 jobs across 10 companies, with heavy concentration in Commercial (640 roles, $246K avg) and Manufacturing (515 roles, $171K avg); AbbVie and Amgen lead hiring despite limited CML-specific portfolio presence, suggesting broader oncology integration. Top salaries in Commercial track ($246K) make this attractive for field-based roles; R&D roles ($182K) limited as pipeline is mature.
Top Hiring Companies
By Department
Strong commercial and manufacturing hiring suggests CML remains operationally critical despite mature market; limited R&D expansion indicates consolidation at the innovation layer.
On Market (1)
Approved therapies currently available
Competitive Landscape
24 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 42 trials with date data
Clinical Trials (42)
Total enrollment: 9,606 patients across 42 trials
A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
Nilotinib Plus Pegylated Interferon-α2b in CML
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
TGRX-678 Pharmacokinetic Mass Balance
TGRX-678 Phase I Oral Pharmacokinetic Study
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
Special Drug Use-results Surveillance of Scemblix Tablets
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications
Study Conducted Among Patients With CML
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
Iclusig PMS in CML or Ph+ALL Patients
Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Related Jobs in Oncology
Medical Director Hematology, US OBU Medical Affairs
Associate Clinical Oncology Specialist
Sr Marketing Manager, NPP HCP Marketing
Principal Scientist, Oncology Drug Discovery
Associate Director, Diagnostic Planning Lead - Oncology
Manager, Medical Affairs
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.